ALPHA.PA

Pharnext SA [ALPHA.PA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ALPHA.PA Stock Summary

In the News

ALPHA.PA Financial details

Company Rating
-
Market Cap
42.29K
Income
-67.73M
Revenue
1.23M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
23
Optionable
No
Shortable
Yes
Earnings
20 Apr 2024
P/E
0
Forward P/E
-
PEG
-
P/S
311.6
P/B
-
P/C
-
P/FCF
-0.01
Quick Ratio
0.03
Current Ratio
0.3
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
1287675.07B
EPS next Y
-
EPS next Q
-
EPS this Y
-99.92%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-75.17%
Revenue last 5Y
-84.78%
Revenue Q/Q
-85.81%
EPS Q/Q
266346600.99%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-491%
ROE
152%
ROC
2.09%
Gross Margin
100%
Oper. Margin
-4985304%
Profit Margin
-6906213%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.175-8.04E7
52W High
-
52W Low
-
RSI
-
Rel Volume
309.56
Avg Volume
18.53K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-315.381
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
ABEC.DE
1YD.DE
EMBASSY.NS
DHR-PB
NVDA
Same Sector
MRMD
5187.T
0512.HK
RGMP
CMMB
Check Those
KTF
RMCF
ALBLU.PA
XFS.TO
SANB11.SA
Similar Market Cap
URYL
ALPHA.PA
RMGCW
XBOR
AMIH

Company Profile

Healthcare Biotechnology
  • Volume Average 18.53K
  • Market Capitalization 42.29K
  • Employee 23
  • CEO Mr. Hugo Brugiere M.Sc.
  • Headquarters Issy-les-Moulineaux,FR
  • IPO Date 2016-07-18
  • Website https://www.pharnext.com

Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.